Sonnet biotherapeutics announces 1-for-8 reverse stock split

Princeton, n.j., sept. 25, 2024 (globe newswire) -- sonnet biotherapeutics holdings, inc. (“sonnet” or the “company”) (nasdaq: sonn), a biopharmaceutical company developing innovative targeted biologic drugs, announced today that it will effect a 1-for-8 reverse stock split of its outstanding common stock. this will be effective for trading purposes as of the commencement of trading on monday, september 30, 2024.
SONN Ratings Summary
SONN Quant Ranking